Trial of Parkinson's Cell Therapy to Follow Bayer Acquistion of BlueRock Therapeutics


Its lead program is in Parkinson’s, where preclinical work using BlueRock’s induced pluripotent stem cell (iPSC) technology has shown motor function improvement and higher dopamine production by stem cell-derived dopamine-producing neurons — those that are typically lost in distinct brain regions of Parkinson’s patients.


Also:
Parkinson's Gene Therapy in Clinical Trial, AXO-Lenti-PD, Safe And Effective in Monkey Model of Disease, Study Says